Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673061 · ClinicalTrials.gov registry record · Phase 4
Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage
A Phase 4 study, sponsored by Albert Einstein Healthcare Network.
- Terminated
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT01673061 is a Phase 4 study that was terminated before completion, run by Albert Einstein Healthcare Network. The registered enrollment target is 21 participants.
The verdict
NCT01673061, a Phase 4 study, was terminated before completion, sponsored by Albert Einstein Healthcare Network.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
Cutaneous abscesses (boils) are collections of pus or infection in the skin, and are a frequent reason for emergency department visits. The only proven cure for abscesses is cutting them open and allowing the infection to drain, but this procedure is often painful. Currently, the usual method of pain control is to inject a numbing medication (lidocaine) into the site, but this injection itself is often painful and sometimes does not offer full pain relief. Although there has been some research into the use of non-injected numbing agents as another option, no studies have looked at the use of numbing sprays (vapocoolant) in this context specifically. The hypothesis of this study is that numbing spray is as good as injected numbing medication at relieving pain in patients having small abscesses opened and drained. This theory will be tested by taking two groups of patients having small abscesses drained in the Emergency Department, and assigning one group to get a numbing injection, and the other to get a numbing spray. Their levels of pain and satisfaction will be recorded before, during, and after the procedure, and the two groups will be compared.
Interventions
- DRUG Lidocaine
- DRUG Vapocoolant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673061
The ClinicalTrials.gov registry entry for NCT01673061 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein Healthcare Network, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lidocaine is the first listed.
NCT01673061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01673061 about?
NCT01673061 is a clinical study titled "Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage". Cutaneous abscesses (boils) are collections of pus or infection in the skin, and are a frequent reason for emergency department visits. The only proven cure for abscesses is cutting them open and allowing the infection to drain, but this procedure is often painful. Currently, the usual method of pai...
What is the current status of trial NCT01673061?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2012-08. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01673061?
The interventions under investigation include: Lidocaine (DRUG), Vapocoolant (DRUG).
Who is sponsoring clinical trial NCT01673061?
This trial is sponsored by Albert Einstein Healthcare Network, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.